31.2 C
New York
Thursday, July 3, 2025

Tag: prescription

Robotic Surgery Market 2025 Trends: Advanced AI Systems, Telesurgery and $400M Investments Power Global Expansion

The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.
The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.

Fangzhou Tops China’s App Store Chart for Healthcare Apps

GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in...

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Nuwellis Appoints John Erb as Chief Executive Officer

Nuwellis Announces Appointment of John Erb as Chief Executive Officer

CENTENE CORPORATION WITHDRAWS 2025 GUIDANCE

ST. LOUIS, July 1, 2025 /PRNewswire/ -- Centene Corporation (NYSE: CNC) (Centene, the Company) is withdrawing its previous 2025 GAAP and adjusted diluted earnings per...

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Effective Testosterone Booster for Men Over 50: TestoPrime Medically Accredited as the Best Testosterone Supplement for Males In 40’s and 50’s

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription
Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription

SAFILO GROUP AND VICTORIA BECKHAM ANNOUNCE A TEN-YEAR GLOBAL LICENSING AGREEMENT FOR EYEWEAR COLLECTIONS

PADUA, Italy and LONDON, July 1, 2025 /PRNewswire/ -- Safilo Group – one of the eyewear industry's key players in the design, manufacturing and distribution...

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio

BleeqUp Showcases Revolutionary AI Cycling Glasses at Eurobike 2025

FRANKFURT, Germany, June 30, 2025 /PRNewswire/ -- BleeqUp, an AI-powered outdoor sports technology brand, showcased its groundbreaking BleeqUp Ranger at Eurobike 2025. Hailed as...

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead the Sarepta...

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s top executives with violations of the Securities Exchange Act of 1934.

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

CCHR Calls for Immediate Ban on Electroshock Treatment Across Europe

Citizens Commission on Human Rights (CCHR) groups from across Europe protested in Madrid during the 33rd European Congress of Psychiatry, demanding an end to coercive...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrescription